Herpes Zoster Therapeutics Market Size in the 7MM is expected to grow by 2034, estimates DelveInsight

DelveInsight's "Herpes Zoster Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of the Herpes Zoster, historical and forecasted epidemiology as well as the Herpes Zoster market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Discover Key Insights into the Herpes Zoster Market with DelveInsight's In-Depth Report @ Herpes Zoster Market Size [https://www.delveinsight.com/sample-request/herpes-zoster-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Herpes Zoster Market Report

* In November 2024:- Sanofi Pasteur, a Sanofi Company- To assess the safety profile of each SP0202 formulation and Prevnar 13 in toddlers and infants (after each and any injection). To assess the immune response (serotype specific IgG concentration) of the SP0202 formulations and Prevnar 13 1 month after the administration of one dose in toddlers (Groups 1-4).
* According to analysis, approximately one in every three individuals residing in the United States will experience an episode of shingles, medically referred to as herpes zoster, during their lifetime. It is estimated that around one million individuals are affected by shingles annually within the country.
* Based on our secondary analysis, in Japan the herpes zoster prevalence among individuals in the general population aged 50 years and above is approximately 10 per 1000 person-years (PY), with a higher prevalence observed among those aged 60 years and above. Moreover, the incidence escalates to more than 12 per 1000 PY in individuals aged 80 years and older.
* Among the 7MM, the lowest number of healthy patient population at-risk for herpes zoster was found to be in Spain.
* Assessments showed that among the European countries, Germany had the highest eligible patient population for herpes zoster vaccination and and are expected to increase by 2034.
* Elderly individuals and those with weakened immune systems, considered high-risk groups, may encounter cumulative incidences of up to 50%.
* The leading Herpes Zoster Companies such as Curevo Inc., Mogam Biotechnology Research Institute, Green Cross Corporation, Immoma Biotherapeutics Inc., Icon Plc, Pascoe Pharmazeutische Praeparate GmbH, GlaxoSmithKline, Astellas Pharma Inc., Yung Shin Pharm Ind. Co. Ltd., Jiangsu Rec-Biotechnology Co., Ltd., Maruho Co. Ltd., Epiphany Biosciences, EMS, Nobelpharma, Bristol-Myers Squibb , and others.
* Promising Herpes Zoster Therapies such as JCXH-105, TNM005, CRV-101 Vaccine Antigen High Dose, mRNA-1468, PF-07915234, HZ/su vaccine, Herpes Zoster Vaccine GSK1437173A, Varicella Zoster Vaccine , and others

Stay ahead in the Herpes Zoster Therapeutics Market with DelveInsight's Strategic Report @ Herpes Zoster Market Outlook [https://www.delveinsight.com/sample-request/herpes-zoster-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Herpes Zoster Epidemiology Segmentation in the 7MM

* Total Healthy Patient Population at-risk for Herpes Zoster
* Eligible Patient Population for Herpes Zoster Vaccination

Download the report to understand which factors are driving Herpes Zoster Epidemiology trends @ Herpes Zoster Prevalence [https://www.delveinsight.com/sample-request/herpes-zoster-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Marketed Herpes Zoster Therapies

* Shingrix : GlaxoSmithKline (GSK)

Shingrix (herpes zoster vaccine recombinant, adjuvant), also known as GSK1437173A is a non-live, recombinant subunit vaccine that help prevent Herpes Zoster (herpes zoster) in adults 50 years of age and older. The vaccine combines an antigen, glycoprotein E, and an adjuvant system, AS01B, intended to generate a strong and long-lasting immune response that can help overcome the decline in immunity that occurs as people age. Shingrix is given intramuscularly in two doses. Shingrix is currently licensed for use in the EU, US, Canada, Japan, China, and Australia.

Emerging Herpes Zoster Therapies

* CRV-101: Curevo Inc.

CRV-101 is an investigational adjuvanted subunit vaccine under investigation for the prevention of Herpes Zoster in older adults. CRV-101 was specifically designed to produce an optimal immune response while using a smaller amount of adjuvant with the intention of achieving similar efficacy but with fewer side effects than the currently-approved Herpes Zoster vaccine. On September 2022, Curevo announced completion of enrollment in a Phase IIb trial of their CRV-101 subunit vaccine to prevent the reactivation of the varicella zoster virus (shingles) in older adults.

To know more about Herpes Zoster treatment guidelines, visit @ Herpes Zoster Treatment Market Landscape [https://www.delveinsight.com/sample-request/herpes-zoster-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Herpes Zoster Therapies and Companies

* JCXH-105: Immorna Biotherapeutics, Inc./ICON plc
* TNM005: Zhuhai Trinomab Pharmaceutical Co., Ltd.
* CRV-101 Vaccine Antigen High Dose: Curevo Inc/Green Cross Corporation
* mRNA-1468: ModernaTX, Inc.
* PF-07915234: Pfizer
* HZ/su vaccine: GlaxoSmithKline
* Herpes Zoster Vaccine GSK1437173A: GlaxoSmithKline
* Varicella Zoster Vaccine: Bristol-Myers Squibb

Herpes Zoster Market Dynamics

The herpes zoster market dynamics have undergone significant changes over the years. Firstly, the aging population is a significant driver. As the global population continues to age, the risk of developing herpes zoster increases, creating a growing patient pool for antiviral medications and vaccines. Additionally, advancements in medical research and development have brought new treatments and vaccines to the market. Vaccination campaigns, such as the introduction of the varicella-zoster vaccine, have helped reduce the incidence and severity of herpes zoster. This, in turn, affects the demand for antiviral medications and preventive treatments.

Learn more about the FDA-approved drugs for Herpes Zoster @ Drugs for Herpes Zoster Treatment [https://www.delveinsight.com/sample-request/herpes-zoster-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Herpes Zoster Market Report

* Coverage- 7MM
* Study Period- 2020-2034
* Herpes Zoster Companies- Immorna Biotherapeutics, Inc., ICON plc, Zhuhai Trinomab Pharmaceutical Co., Ltd., Curevo Inc, Green Cross Corporation, ModernaTX, Inc., Pfizer, GlaxoSmithKline, Bristol-Myers Squibb, and others
* Herpes Zoster Therapies- JCXH-105, TNM005, CRV-101 Vaccine Antigen High Dose, mRNA-1468, PF-07915234, HZ/su vaccine, Herpes Zoster Vaccine GSK1437173A, Varicella Zoster Vaccine, and others
* Herpes Zoster Unmet Needs, KOL's views, Analyst's views, Herpes Zoster Market Access and Reimbursement

Table of Content

1. Key Insights

2. Report Introduction

3. Herpes Zoster (Shingles) Market Overview at a Glance

4. Herpes Zoster Epidemiology and Market Methodology

5. Herpes Zoster Executive Summary

6. Key Events

7. Herpes Zoster Disease Background and Overview

8. Herpes Zoster Epidemiology and Patient Population

9. Herpes Zoster Patient Journey

10. Herpes Zoster Marketed Products

11. Herpes Zoster Emerging Treatment and Management

12. Herpes Zoster: 7 Major Market Analysis

13. Herpes Zoster SWOT Analysis

14. Herpes Zoster KOL Views

15. Herpes Zoster Unmet Needs

16. Herpes Zoster Market Access and reimbursement

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=herpes-zoster-therapeutics-market-size-in-the-7mm-is-expected-to-grow-by-2034-estimates-delveinsight]
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/respiratory-domain-conference-coverage



This release was published on openPR.